Roth Comments on Galena's (GALE) Expanded NeuVax, Trastuzumab Enrollments; Affirms 'Buy' Rating
Tweet Send to a Friend
Roth Capital affirms Galena Biopharma (Nasdaq: GALE) with a Buy rating and price target of $8 announced that human leukocyte ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
